A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
about
Recent advances in treatment of advanced urothelial carcinoma.Novel agents for advanced bladder cancer.Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.Current therapeutic strategies for invasive and metastatic bladder cancer.Chemotherapy in advanced bladder cancer: current status and futureThe safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experiencePhase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).Personalized therapy for urothelial cancer: review of the clinical evidence.Systemic therapy for metastatic urothelial carcinoma.Current optimal chemotherapy for advanced urothelial cancer.Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology GroupPhase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review.New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
P2860
Q33565845-C982DDB6-0F92-4B43-8292-9137E8750657Q35076184-DB019C75-4356-4196-BEF7-143EAAA4E09AQ35076309-30F7CE98-A48B-4021-851A-E2E5DC4835E8Q35128721-2D969B6C-40B3-447A-9170-CD22C172CB2FQ35227771-9A8E65E7-7325-453A-A7C0-089414DBA14CQ35586693-32AF1E6D-880C-4BFE-BCA4-F5B47F3A2727Q35677288-3D22C1C0-6796-43D6-A601-FCC66C540D7CQ36062762-019033B0-D816-4F34-8FA2-EB927B7E7A42Q37028356-ACB4FD71-4E2E-47DB-8BBB-B605D138CE72Q37038897-6695ACFD-D25D-4B5F-A400-A43DB1ED099EQ37172835-3A26119D-A4AC-42DA-ADC3-242614B77B07Q37439034-547AA9D1-B742-461D-8F5A-CC7062A29B28Q37896172-A24FAF00-498D-4A97-A465-31D7482C2F7DQ38669606-1086F5EE-F59C-4B30-840C-D0F650A11A3BQ38673585-29E59EF6-8FB5-4A88-90EA-7096842BCBEDQ38701535-04516910-219A-4F8B-8531-2CDBDB93586FQ40345312-BDBA7D0F-234A-4557-BC53-50AA4AA9792AQ41714739-6D45A8DA-F329-4425-8685-97CC2C9DDD3C
P2860
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase II trial of pemetrexed ...... l carcinoma of the urothelium.
@ast
A phase II trial of pemetrexed ...... l carcinoma of the urothelium.
@en
type
label
A phase II trial of pemetrexed ...... l carcinoma of the urothelium.
@ast
A phase II trial of pemetrexed ...... l carcinoma of the urothelium.
@en
prefLabel
A phase II trial of pemetrexed ...... l carcinoma of the urothelium.
@ast
A phase II trial of pemetrexed ...... l carcinoma of the urothelium.
@en
P2093
P356
P1433
P1476
A phase II trial of pemetrexed ...... ll carcinoma of the urothelium
@en
P2093
H von der Maase
P F Geertsen
P304
P356
10.1093/ANNONC/MDL154
P577
2006-07-27T00:00:00Z